Log In
Print
BCIQ
Print
Print this Print this
 

Anti-IL-20 (NN8226)

Also known as: formerly Anti-IL20

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionRecombinant human mAb neutralizing IL-20
Molecular Target Interleukin-20 (IL-20)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today